Founded in 2017, Dianosic operates in the $50 billion, double digit growth, and still largely underserved market of ENT. The company focuses on Chronic Rhinitis, Chronic Sinusitis and intranasal bleeding (Epistaxis) and has a strong French and German footprint in R&D and manufacturing. Dianosic aims to establish new standards of care in Chronic Rhinitis and Chronic Sinusitis with its drug-eluting Active Resorbable Scaffold (ARIS) platform, which has the potential to create other verticals, especially in the field of chronic migraine and facial pain. In addition, Dianosic commercializes an Asymmetric Intranasal inflatable solution (CAVI-T) for the treatment of intranasal bleeding, which is already present in relevant markets in EU and paving the way to launch in the U.S. in the mid-term.